celecoxib has been researched along with Leukemia, Erythroblastic, Acute in 3 studies
Leukemia, Erythroblastic, Acute: A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Norouzi, S | 1 |
| Norouzi, M | 1 |
| Amini, M | 1 |
| Amanzadeh, A | 1 |
| Nabiuni, M | 1 |
| Irian, S | 1 |
| Salimi, M | 1 |
| Cervi, D | 2 |
| Truong, AH | 1 |
| Lee, JS | 1 |
| Sukhai, N | 1 |
| Li, YJ | 1 |
| Koki, A | 2 |
| Ben-David, Y | 2 |
| Klement, G | 1 |
| Stempak, D | 1 |
| Baruchel, S | 1 |
3 other studies available for celecoxib and Leukemia, Erythroblastic, Acute
| Article | Year |
|---|---|
Two COX-2 inhibitors induce apoptosis in human erythroleukemia K562cells by modulating NF-κB and FHC pathways.
Topics: Apoptosis; Celecoxib; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cyclooxygenase 2 Inhibitor | 2016 |
Phosphorylation status of c-Kit and Epo receptors, and the presence of wild-type p53 confer in vitro resistance of murine erythroleukemic cells to Celecoxib.
Topics: Animals; Antineoplastic Agents; Celecoxib; Drug Resistance, Neoplasm; Leukemia, Erythroblastic, Acut | 2004 |
Targeting cyclooxygenase-2 reduces overt toxicity toward low-dose vinblastine and extends survival of juvenile mice with Friend disease.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cy | 2005 |